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Abstract
Background: Nodular regenerative hyperplasia is an uncommon liver condition associated with several autoimmune dis-
orders and drugs. The clinical symptoms of nodular regenerative hyperplasia vary from asymptomatic to severe complica-
tions of portal hypertension (nodular regenerative hyperplasia-syndrome).
Objective: The purpose of this study was to identify the prognosis and optimal management, as well as the role of liver
transplantation, in nodular regenerative hyperplasia.
Methods: The pathology databases of all three Dutch liver transplant units were retrospectively scrutinised for explanted
livers diagnosed with nodular regenerative hyperplasia or without clear diagnosis. Pre- and post-transplantation clinical,
biochemical, radiological and histological information was obtained from electronic and paper records.
Results: In total, 1886 patients received a liver transplant. In 255 patients, nodular regenerative hyperplasia could not be
excluded. After detailed chart review, the native livers of 11 patients (0.6%) (82% male, median age: 44 years) displayed
nodular regenerative hyperplasia. Seven patients (64%) had underlying disorders or drug exposure which possibly caused
nodular regenerative hyperplasia. Laboratory and imaging abnormalities were present in all patients but did not contribute
to the diagnosis of nodular regenerative hyperplasia. Five-year survival was 73% (median follow-up: four years, range:
2–248 months).
Conclusion: Nodular regenerative hyperplasia is a rare finding in patients, predominantly young males, transplanted for
end-stage liver disease with unknown aetiology. Nonetheless, liver transplantation may have an important role in end-stage
nodular regenerative hyperplasia-syndrome.
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Introduction
Nodular regenerative hyperplasia (NRH) is an uncom-
mon condition of the liver which can cause intrahepatic
portal hypertension in the absence of liver cirrhosis.1–3
Recently, it has been shown that NRH is frequently
asymptomatic and that the histological diagnosis has
to be distinguished from the NRH-syndrome, in
which patients present with symptoms from portal
hypertension.4
The pathophysiology of NRH is still poorly under-
stood, but seems to be related to alterations in the
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hepatic blood ﬂow due to obliterative vasculopathy
and/or secondary to damage of the sinusoids.5 The
development of NRH has been associated with a var-
iety of systemic disorders including myelo- and lympho-
proliferative diseases, autoimmune diseases,
inﬂammatory and immunodeﬁciency disorders as well
as certain medications.6 Drugs associated with NRH
are highly active anti-retroviral therapy,7 platin-based
chemotherapy8 and thiopurines, in particular
azathioprine (AZA) and thioguanine (TG).9–11
The diagnosis of NRH is challenging since the clinical
presentation is variable and the majority of patients pre-
sent without symptoms or abnormalities in laboratory
parameters.12 If symptoms are present, these are mainly
due to portal hypertension, such as thrombocytopenia,
oesophageal varices, splenomegaly and ascites.13 Mildly
increased liver enzymes, in particular alkaline phosphat-
ase (AP), have been reported in one out of 10 patients.6
Imaging methods, such as magnetic resonance imaging
(MRI) and computed tomography (CT) could demon-
strate nodularity and heterogeneous hepatic parenchyma
suggestive of NRH. Nevertheless, diagnosis has to be
conﬁrmed with histological evaluation and a reticulin
stain is necessary to characterise the transformation of
the hepatic parenchyma into hyperplasia and atrophy.14
Interestingly, the level of interobserver agreement on the
histopathologic diagnosis of NRH is poor, even between
experienced liver pathologists, conﬁrming that NRH
should be diagnosed using the combination of clinical
presentation and histopathologic ﬁndings.15
The clinical signiﬁcance and prognosis, as well as the
optimal management of NRH are still not completely
clariﬁed. In a large cohort study by Wanless in 1990,
NRH was present in 64 of 2500 (2.6%) consecutive
autopsies.16 Among these 64 persons, only one had
symptoms of portal hypertension and the other cases
were asymptomatic. It seems that the prognosis in
NRH patients is more related to the severity of the
underlying condition than to liver involvement itself.17
Therefore, treatment should be focused on the asso-
ciated diseases and complications of non-cirrhotic
portal hypertension (NCPH), in particular variceal
bleeding which is the main cause of NCPH-related
mortality.1,18
Liver transplantation might be indicated in NRH-
syndrome and should be considered in patients with
severe complications of NCPH or hepatic failure.19
Frequently, it occurs that the diagnosis of NRH-
syndrome is missed before transplantation and patients
undergo liver transplantation due to a presumptive diag-
nosis of liver cirrhosis.13 Overall, there is limited data
available on the natural course of NRH and the role
of liver transplantation as a treatment. Therefore, we
aimed to determine the number of patients transplanted
due to NRH-syndrome in a retrospective study in The
Netherlands and to evaluate the indications and limita-
tions of this treatment. Here, we describe the clinical
characteristics of the patients and the histological fea-
tures of the explanted livers aﬀected with NRH.
Methods
Patient selection
In this retrospective database study we collected data
from the three liver transplant units in The
Netherlands; University Medical Center Groningen
(UMCG) in Groningen, Erasmus University Medical
Center (EMC) in Rotterdam and Leiden University
Medical Center (LUMC) in Leiden. Access to the surgi-
cal pathology databases was obtained and the records of
patients transplanted in the period from January 1995–
April 2016 were searched for explanted livers diagnosed
with either NRH, non-cirrhotic or cryptogenic liver dis-
ease on post-transplant histological evaluation. We
included all adult patients in our initial analysis.
Explanted livers with hepatic malignancy, hepatitis
B/C virus infection, alcoholic liver disease, primary bil-
iary tract disease, autoimmune hepatitis or metabolic
liver diseases were excluded. Furthermore, cases of pre-
and posthepatic (e.g. Budd-Chiari syndrome) portal
hypertension were excluded. Cases with liver failure due
to other causes of NCPH, such as hepatoportal sclerosis,
perisinusoidal ﬁbrosis or incomplete septal cirrhosis were
excluded, unless NRH co-existed in the major part of the
explanted liver. Cases with acute liver failure related to
(recreational) drugs and medication were included.
Data extraction
Pre- and post-transplantation clinical, biochemical,
radiological and histological information obtained
from electronic and paper records were analysed. We
collected data on demographics, clinical presentation,
medical and surgical history and (historical) lifestyle
(i.e. smoking and alcohol usage) of the patients.
Biochemical parameters we collected were: haemoglo-
bin (Hb), white blood cell count (WBC), platelet count
(PC), alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), alkaline phosphatase (AP),
gamma-glutamyl transferase (GGT), serum bilirubin,
serum creatinine, prothrombin time (PT), international
normalised ratio (INR) and Model for End-Stage Liver
Disease (MELD) scores. Human immunodeﬁciency
virus (HIV) serology was obtained. Further collected
data were macro- and microscopic histological liver fea-
tures related to NRH and characteristics of NCPH,
deﬁned as liver atrophy, heterogeneous parenchyma,
presence of ascites, portal vein thrombosis, portosyste-
mic collateral veins or splenomegaly at ultrasonography
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(US), CT or MRI. The use of potential hepatotoxic
medications (e.g. thiopurines, platin based chemother-
apy and highly active anti-retroviral therapy) was
recorded.
NRH-syndrome
To distinguish histopathological diagnosis of NRH
without symptoms of portal hypertension from patients
with NCPH due to NRH, patients having symptomatic
NRH are classiﬁed as having NRH-syndrome.
Histological analysis
Diagnosis of NRH was based on reports of the histo-
logical assessment of the explanted livers. The macro-
and microscopic features of the liver were explored and
searched for NRH characteristics as deﬁned by Jharap
et al.15 The deﬁnitive diagnosis of NRH based on the
histological reports was made by the pathologist at the
liver transplantation centre.
Data analysis
Categorical variables were described as absolute and
relative numbers. The continuous variables were
described as mean standard deviation (for normal
distribution) or median with range (for skewed distri-
bution). Due to the (expected) low number of patients,
no further statistical analysis was performed.
Ethical considerations
This study was approved by the Medical Ethics Review
Committee (METC) of the VU University Medical
Center (ﬁle number 2016-095).
Results
Patient characteristics
In the past 20 years, 1886 transplantations (UMCG: 660,
EMC: 905 and LUMC: 321) have been performed in
adult patients in the three Dutch liver transplant units.
The database of the LUMC was initiated in 2000. A
total of 255 transplanted patients (UMCG: 79, EMC:
128 and LUMC: 48) matched the inclusion criteria for
this study and their charts were reviewed. NRH was
histologically diagnosed in 11 patients (0.6%) (UMCG:
seven, EMC: three and LUMC: one) (Figure 1).
One of these 11 patients was re-transplanted 14 years
after the initial liver transplantation, both times due to
UMCG
Jan 1995 - Apr 2016
EMC
Jan 1995 - Apr 2016
LUMC
Jan 2000 - Apr 2016
n = 660 n = 905 n = 321
79 128 48
137
11
72 excluded 125 excluded 47 excluded
581 excluded based
on post-Tx histological
diagnosis
777 excluded based
on post-Tx histological
diagnosis
273 excluded based
on post-Tx histological
diagnosis
Figure 1. Flowchart of patient selection. Post-transplantation diagnoses causing exclusion were: hepatic malignancy, hepatitis B/C virus
infection, alcohol abuse, primary biliary tract disease, autoimmune hepatitis and metabolic liver diseases. EMC: Erasmus Medical Center
Rotterdam; LUMC; Leiden University Medical Center; Tx: transplantation; UMCG: University Medical Center Groningen.
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NRH-syndrome. In this study, we only describe the
second liver transplantation, since the ﬁrst transplant-
ation was before 1995. One case has been published
before.20
Among these cases, nine patients were males (82%;
Table 1). The median age at ﬁrst presentation with liver
disease was 27 years (range: 18–60 years) and 44 years
at time of the liver transplantation (22–69 years). The
delay between ﬁrst presentation and liver transplant-
ation ranged from 4–20 years with a median delay
time of nine years.
The pre-transplantation diagnosis was cryptogenic
cirrhosis for seven patients (7/11; 64%), alcoholic cirrho-
sis for two patients (2/11; 18%), autoimmune hepatitis
(AIH) for one patient (1/11; 9%) and one patient was
diagnosed with antimitochondrial antibody (AMA)-
negative primary biliary cirrhosis (PBC) (1/11; 9%).
Clinical presentation of the NRH patients
Four patients (4/11; 36%) had unexplained liver test
abnormalities, four patients (4/11; 36%) were bleeding
from gastro-oesophageal varices and three patients (3/
11; 28%) had thrombocytopaenia at ﬁrst clinical pres-
entation (Table 1). Therapeutic management to treat
the acute variceal bleeding was endoscopic band liga-
tion (2/4; 50%) or sclerotherapy followed by a surgical
portocaval shunt (1/4; 25%) or splenorenal shunt (1/4;
25%). During the pre-transplantation course, more
complications of portal hypertension occurred in all
patients. The most frequently occurring complications
were gastro-oesophageal varices (11/11; 100%), spleno-
megaly (10/11; 91%), portal vein thrombosis (7/11;
64%), ascites (7/11; 64%) and hepatic encephalopathy
(4/11; 36%). Furthermore, three patients had spontan-
eous bacterial peritonitis (3/11; 28%) and three patients
developed hepatopulmonary syndrome (HPS, 3/11;
28%), which is an important cause of dyspnoea and
hypoxia in the setting of end-stage liver disease.
Diseases and drugs associated with NRH
An associated disease and/or drug use with NRH was
observed in seven of 11 patients (7/11; 64%), of which
ﬁve patients (5/11; 45%) were treated with thiopurines.
These seven patients together had a median age of 27
years (23–46 years) when ﬁrst liver symptoms devel-
oped and a median age of 44 years (30–54 years)
when orthotopic liver transplantation (OLT) was per-
formed. Patient #3 underwent OLT for the second time,
both times due to NRH-syndrome. After ﬁrst OLT, this
patient was treated with AZA for nine years and even-
tually developed liver failure 14 years after initial OLT.
Patient #4 was previously diagnosed with autoimmune
hepatitis (AIH) and was treated with AZA 150mg/day
for six months before manifestation of NRH-
Table 1. Clinical findings in the patients with nodular regenerative hyperplasia (NRH) before orthotopic liver transplantation (OLT).
Case
no. Sex Agea
Associated diseases
and medication
Symptoms
first presentation
Varices,
grade:
Spleno-
megalyb Ascitesc
Other
complications Diagnosis pre-OLT
1 M 26–45 ITP Thrombopaenia III Yes Yes PVT Cryptogenic cirrhosis
2 F 23–41 ITP, AIHA Thrombopaenia III N/Ad No HPS, PVT Cryptogenic cirrhosis
3 M 61–63e MGUS, AZA, post-OLT Bleeding varices I Yes Yes HPS Cryptogenic cirrhosis
4 F 46–54 MGUS, AZA Thrombopaenia I Yes Yes HE Autoimmune hepatitis
5 M 27–44 Renal Tx, AZA ELE III Yes Yes PVT Cryptogenic cirrhosis
6 M 41–46 UC, AZA, MP ELE II Yes Yes SBP, PVT Alcoholic liver cirrhosis
7 M 26–30 ALL, UC, TG,
MTX cytoxan,
doxorubicin
Bleeding varices I Yes No PVT, HE Cryptogenic cirrhosis
8 M 24–43 Idiopathic ELE II Yes No None AMA-PBC
9 M 18–22 Idiopathic ELE II Yes No HE Cryptogenic cirrhosis
10 M 27–37 Idiopathic Bleeding varices III Yes Yes SBP, HPS, PVT, HE Alcoholic liver cirrhosis
11 M 60–69 Idiopathic Bleeding varices II Yes Yes SBP, PVT Cryptogenic cirrhosis
AIHA: autoimmune haemolytic anaemia; ALL: acute lymphoblastic leukaemia; AMA-PBC: antimitochondrial antibody-negative primary biliary cirrhosis;
AZA: azathioprine; ELE: elevated liver enzymes; F: female; HE: hepatic encephalopathy; HPS: hepatopulmonary syndrome; ITP: immune-mediated thrombo-
cytopenia; M: male; MP: mercaptopurine; MGUS: monoclonal gammopathy of undetermined significance; MTX: methotrexate; PVT: portal vein thrombosis;
SBP: spontaneous bacterial peritonitis; TG: thioguanine; Tx: transplantation; UC: ulcerative colitis.
aAge at first presentation and age of OLT; bsplenomegaly was defined as a longest diameter above 11 cm; cascites was evaluated using abdominal
ultrasound; dthis patient underwent a splenectomy prior to the development of NRH; ethis patient underwent a liver transplantation for the second time due
to NRH.
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syndrome. Revision of the histology did not conﬁrm
AIH, and AZA was subsequently discontinued. The
remaining four patients (36%) were neither diagnosed
with an associated disease nor treated with hepatotoxic
drugs and presumably developed idiopathic NRH.
Three of them (#8–10) were transplanted at a median
age of 37 years (22–43 years).
Biochemical and imaging results in the
NRH patients
In all patients, laboratory abnormalities were present at
time of referral for OLT. As depicted in Table 2, the
most frequently described abnormalities were anaemia
(10/11, 91%) and thrombocytopaenia (10/11, 91%).
WBC was mildly increased in one patient. Serum
ALT was over two times the upper limit of normal
(ULN) in three patients (28%), in which serum AST
was 2 ULN as well. Serum AP was (mildly) increased
in eight patients (73%), out of which three patients
(28%) had levels 2 ULN and GGT was 2 ULN in
four patients (36%). Total bilirubin was increased in all
patients, out of which eight patients (73%) had levels
over two times ULN. The international normalised
ratio was 1.5 in ﬁve patients (46%) and serum cre-
atinine was 100 mmol/l in three patients (27%).
The MELD scores at time of referral for OLT varied
from 8–24 with a median of 18. In all patients Hepatitis
B virus (HBV), Hepatitis C virus (HCV) and HIV ser-
ology, rheumatoid factor, protein C and antibodies for
autoimmune liver diseases were negative. Furthermore,
levels of ferritin, copper, a-foetoprotein and a1-antitryp-
sin were within normal limits.
In the pre-transplantation course, signs of portal
hypertension were observed by imaging methods in all
patients, but NCPH and/or NRH was not diagnosed in
any of the patients by the radiologist (Table 2). The
most frequent characteristics of portal hypertension,
detected at US or CT were splenomegaly (10/11,
91%), portal vein thrombosis (7/11, 64%), portosyste-
mic collateral veins (7/11, 64%), ascites (7/11, 64%),
heterogeneous liver parenchyma (5/11, 46%) and an
atrophic liver (4/11, 36%).
Histological analysis of the explanted livers
Results of histological analysis at liver biopsy before OLT
were available in nine patients (absent in #5 and #9).
Table 2. Laboratory and imaging findings in the patients with nodular regenerative hyperplasia (NRH) before orthotopic liver trans-
plantation (OLT).
Case no. 1 2 3 4 5 6 7 8 9 10 11
Laboratory findings (normal value)
Hb (7.5–11mmol/l) 8.1 5.9 6.2 6.2 3.8 5.6 6.6 6.2 4.8 6.0 6.1
WBC (3.5–10 109/l) 4.7 2.7 7.7 7.5 13.1 6.6 7.1 2.8 2.7 4.6 6.6
PC (150–400 109/l) 47 30 68 188 75 126 57 38 33 60 81
ALT (<45 U/l) 19 47 42 52 40 118 300 36 582 37 86
AST (<40 U/l) 27 60 78 67 45 131 600 31 438 62 60
AP (<120 U/l) 101 156 276 144 69 133 77 131 1356 267 182
GGT (<55 U/l) 61 149 148 90 56 200 63 44 16 53 218
Bilirubin (<20 mmol/l) 24 25 203 23 115 311 47 132 41 60 197
Albumin (35–50 g/l) 38 28 31 28 30 22 15 38 31 24 43
INR 1.3 1.3 1.3 1.1 1.5 1.8 1.3 1.8 1.7 1.5 1.1
Creatinine (50–100 mmol/l) 86 40 109 70 216 46 100 52 45 25 95
MELD score 11 11 20 8 26 24 16 21 16 16 26
Findings at US/CT abdomen
Splenomegaly Yes N/Aa Yes Yes Yes Yes Yes Yes Yes Yes Yes
Ascites Yes No Yes Yes Yes Yes No No No Yes Yes
Atrophy liver Yes Yes No No No Yes No No Yes No No
Heterogeneous liver No No Yes Yes No Yes Yes No No No Yes
PVT Yes Yes No No Yes Yes Yes No No Yes Yes
PSCV Yes No No No Yes Yes Yes Yes Yes Yes No
ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotransferase; CT: computed tomography; GGT: gamma-glutamyl transferase;
INR: international normalised ratio; Hb: haemoglobin; MELD: Model for End-Stage Liver Disease; N/A: not applicable; PC: platelet count; PSCV: portosys-
temic collateral veins; PVT: portal vein thrombosis; US: ultrasonography; WBC: white blood cell count.
aThis patient had a splenectomy in the surgical history.
662 United European Gastroenterology Journal 5(5)
As summarised in Table 3, suggestive presence of NRH
was reported by the local pathologist in four patients (4/9;
44%). In three patients (3/9; 33%) histological features of
non-cirrhotic liver disease were seen, but NRH was not
reported. There were no histological signs of non-cirrhotic
liver disease or NRH reported in the liver biopsies of the
remaining two patients (2/9; 22%).
Histopathological examination of the explanted
livers was performed in all 11 cases. Histological cri-
teria of cirrhosis was lacking in all explanted livers.
Explanted livers were atrophic with a mean weight of
1020 110 g. In liver #6 NRH co-existed with focal
hepatoportal sclerosis and in liver #8 NRH co-existed
with focal incomplete septal cirrhosis. The other nine
livers (9/11; 82%) were diagnosed with pure NRH.
Dysplasia or neoplasia was not reported in any of the
explanted livers.
Post transplantation; mortality and follow-up
Six out of 11 patients (6/11; 55%) are currently alive.
Two patients (#2 and #10) died shortly after liver trans-
plantation and three patients died during follow-up
(#1, #3 and #5, median follow up: 10 years). The one-
year and ﬁve-year survival rate in this population of
patients was 82% and 73%, respectively. In all three
patients who died within ﬁve years after transplant-
ation, HPS co-existed with end-stage liver disease.
Clinical follow-up in the nine patients who recovered
well from OLT ranged from two months to 21 years,
with a median follow-up of four years. These results are
summarised in Table 4.
During the follow-up, no acute rejection was
observed in any of the patients. Recurrence of severe
NCPH complications did occur in patient #3 due to
NRH, 14 years after initial OLT. In the 14 months
after his second OLT, no recurrence of liver disease
has been observed. Complications of NCPH did not
re-occur in the other patients, nor was histological
recurrence of NRH observed in the patients who under-
went liver biopsy.
Discussion
This is the largest study reported to date, describing
the number of patients transplanted due to
Table 3. Histopathological findings in the livers at liver biopsy and orthotopic liver transplantation (OLT).
Case
no.
Liver biopsy
pre-OLTa Histological features explanted liver Diagnosis Weight (g)
1 OLT-1:
No abnormality
Micronodularity, sinusoidal dilatation, atrophy of hepatocytes
and increased hepatocyte layers
Pure NRH 950
2 OLT-6:
No abnormality
Micronodularity without fibrosis, dilated intrahepatic veins,
atrophic hepatic cell plates, PVT
Pure NRH 760
3 OLT-2:
NRH
Micronodularity, sinusoidal dilatation, atrophy of hepatocytes,
increased hepatocyte layers, minimal fibrosisb
Pure NRH 1352
4 OLT-6:
NRH
Nodularity without fibrosis, dilated intrahepatic veins, sinusoidal
dilatation and atrophy of hepatocytes
Pure NRH 794
5 Not available Nodules distinguished by hepatocytes with atrophy, increased
hepatocyte layers, minimal fibrosis and sinusoidal dilatation
and PVT
Pure NRH 944
6 OLT-5:
No cirrhosis
Lesions with sclerosis, obliteration of portal venules and lesions
with nodules without fibrosis
NRH co-existing with focal
hepatoportal sclerosis
1275
7 OLT-3:
No cirrhosisc
Micronodularity , minimal fibrosis, sinusoidal dilatation, atrophy
of hepatocytes and increased hepatocyte layers
Pure NRH 974
8 OLT-7:
NRH
Nodules with incomplete septa, focal lesions of micronodularity,
atrophy, increased hepatocyte layers and sinusoidal dilatation
NRH co-existing with focal
incomplete septal cirrhosis
1145
9 Not available Nodules distinguished by hepatocyte with atrophy, increased
hepatocyte layers, sinusoidal dilatation and PVT
Pure NRH 1017
10 OLT-5:
NRH/PNT
Varying micro- and macronodules with minimal fibrosis, dilated
intrahepatic veins, sinusoidal dilatation and PVT
Pure NRH 990
11 OLT-0:
No cirrhosis
Micronodularity with minimal fibrosis, increased hepatocyte
layers, focal cholestasis and steatosis
NRH with focal hepatitis 1020
NRH: nodular regenerative hyperplasia; PNT: partial nodular transformation; PVT: portal vein thrombosis.
aOLT-x: x¼ number of years between the time of liver biopsy and OLT; bpatient with re-transplantation due to NRH, the same histological features were seen
in the first as second explanted liver; cthis patient was treated with methotrexate for acute lymphoblastic leukaemia, there were no signs of liver damage
due to methotrexate in particular.
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NRH-syndrome in a 20-year cohort study amongst all
liver transplant centres in the Netherlands. Out of 1886
performed liver transplantations, records of 255
patients who underwent OLT for NRH, non-cirrhotic-
or cryptogenic liver disease were scrutinised. Eleven
patients with NRH on histological evaluation of their
explanted livers were identiﬁed, suggesting a percentage
of 0.6% of liver transplantations due to NRH-
syndrome based on nationwide pathology data.
We reported clinical, biochemical, radiological and
histological ﬁndings of 11 patients and their explanted
livers. A male predominance (9/11; 82%) with a median
age of 44 years at OLT was detected, similar to the
numbers which are reported on NRH and liver trans-
plantation in the literature.21–23 This male predomin-
ance in severe NRH-syndrome needing OLT has been
reported before, however the explanation remains
unclear. All our presented patients had a progressive
clinical course including severe complications of
NCPH. The abnormalities in biochemical and imaging
studies were not suggestive for NCPH or NRH and all
of our patients were presumed to have liver cirrhosis in
the pre-transplantation course. The majority of our
patients (55%) did not have elevated liver enzymes,
but anaemia (91%) and thrombocytopaenia (91%)
were present in almost all of them. Six patients (55%)
had portal vein thrombosis alongside NRH, which is
consistent with other reports showing coagulation dis-
orders in NRH patients.24
To our knowledge, this is the ﬁrst study describing
the number of patients transplanted due to NRH-
syndrome in a nationwide database of liver transplants
in The Netherlands in a time period of over 20 years.
Comparable studies assessed smaller cohorts
(maximum of four patients) and a review described 33
patients transplanted due to NRH-syndrome19,31–34 as
depicted in Table 5.
The MELD score at referral for OLT was highly
variable and varied from 8–24, without predicting pro-
gression and severity of NRH-syndrome, probably due
to the fact that liver synthesis function in NRH
patients remains normal in severe NRH, which was
underlined in the systematic review on liver transplant-
ation for NRH by Manzia et al.19 before. One of the
suggestions for further research is to determine mortal-
ity in NRH patients on the waiting list for liver trans-
plantation, to justify modifying the MELD score for
NRH patients.
Histological NRH is associated with several auto-
immune diseases and drug exposure. Interestingly, not
all patients in our cohort had a medical history of dis-
eases and/or drug use related to NRH and we presume
that NRH occurred idiopathically in some of the
patients (36%). Five patients (45%) were treated with
chemotherapy and thiopurines, in line with other
reports.10,11,35 In one of these studies, an NRH inci-
dence rate of 62% in patients treated with high-dose
TG was reported and it was concluded that TG
should not be considered as a therapy for patients
with inﬂammatory bowel disease (IBD).10 However, in
some studies, it was shown that the formation of NRH
appears to be dose dependent and that histopatho-
logical liver abnormalities are relatively common in
IBD patients, even without exposure to thiopur-
ines.36–38 Lastly, two of our patients were known with
immune-mediated thrombocytopenia (ITP) without
exposure to thiopurines or other NRH-related drugs,
a relation which has been described previously.39
Table 4. The post-transplantation course in the patients with nodular regenerative hyperplasia (NRH).
Case
no. Post transplantation course Status
Follow-up
(time in months)
Recurrence
NRH
1 Successful recovery, normal follow-up, died 10 years after OLT Dead 118 No
2 Died seven days after OLT due to ARDS Dead – –
3 Died 14 months after OLT due to cerebral haemorrhage Dead 14 Yesa
4 Successful recovery, normal follow-up Alive 2 No
5 Relaparotomy due to leakage, normal follow-up, died 15 years after OLT Dead 180 No
6 Relaparotomy due to leakage, normal follow-up Alive 6 No
7 Successful recovery, normal follow-up Alive 187 No
8 Prolonged recovery due to anastomotic stenosis, suspected sarcoidosis Alive 44 No
9 Successful recovery, normal follow up Alive 248 No
10 Relaparotomy due to leakage, died 2 months after OLT due to sepsis Dead – –
11 TB in transplanted liver activated in 4 months after OLT Alive 31 No
ARDS: acute respiratory distress syndrome; OLT: orthotopic liver transplantation; TB: tuberculosis.
aThis patient had a recurrence of symptomatic NRH at 14 years after first liver transplantation, there was no recurrence of NRH after second OLT.
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One of the limitations of our study design is the fact
that we recruited our patients based on the histological
evaluations made by the pathologists on location in the
participating centres. Whereas all our included patients
had symptoms of portal hypertension, the histological
diagnosis of NRH remains challenging due to diﬀerent
interpretations of histological features by pathologists,
as demonstrated in a study by Jharap et al.15 For our
study, we did not histologically reassess the explanted
liver specimens of our patients. Reviewing the liver spe-
cimens by an experienced pathologist would improve
the methodological power of this study.
Table 5. Published studies on patients transplanted due to nodular regenerative hyperplasia (NRH) and their patient characteristics.
Authors Year n Sex Agea Follow-up (months) Status Risk factors
McDonald et al.13 1990 1 M 47 4 Dead Alo, NepS
Elariny et al.25 1994 1 F 44 24 Alive HepC, HS
Gane et al.26 1994 3 M 23 – Alive AZA
F 20 – Alive AZA
F 28 – Alive AZA
Loinaz et al.22 1998 4 M 37 84 Alive Alcohol
M 41 65 Alive AZA
M 37 3 Dead HepC
M 25 1 Dead None
Dumortier et al. 1999 2 M 59 33 Alive None
M 40 10 Alive None
Radomski et al.21 2000 4 M 45 48 Alive None
M 48 46 Alive None
M 54 43 Alive None
F 39 24 Alive None
Dumortier et al.23 2001 3 M 49 102 Alive Unknownb
M 41 24 Alive Unknownb
M 63 48 Alive Unknownb
Jawaid et al.27 2003 1 M 51 24 Alive None
Buchel et al.28 2005 1 M 51 24 Alive HHC
Krasinskas et al.34 c 2005 – – – – – –
Devarbhavi et al.29 2007 3 F 55 – Dead Tac/P/MMF
M 56 1 Dead Cys/P/AZA
M 48 48 Alive Cys/P/AZA
Tateo et al.30 2008 3 F 38 9 Alive HAART
F 38 4 Alive HAART
M 43 7 Alive HAART
Maganty et al.31 2011 1 F 26 15 Alive None
Sultanik et al.32 2013 4 F 38 77 Alive HAART
F 38 9 Dead HAART
M 43 63 Alive HAART
M 44 27 Alive HAART
Gorgy et al.33 2015 2 M 35 7 Dead STS
M 39 1 Dead STS
Alo: alopecia totalis; AZA: azathioprine; Cys: cyclosporin; F: female; HAART: highly active anti-retroviral therapy; HepC: chronic hepatitis C infection; HHC:
hyperhomocysteinaemia; HS: haemosiderosis; M: male; MMF: micophenolate mofetil; NepS: nephrotic syndrome; P: prednisone; STS: short telomere
syndrome; Tac: tacrolimus.
This table is modified from the systematic review on liver transplantation for NRH by Manzia et al.19 and completed till April 2016 with the studies by
Maganty et al.,25 Sultanik et al.,26 Gorgy et al.27 and Krasinkas et al.28
aAge at time of liver transplantation; brisk factors not mentioned in article; cthis study was neither included in the systematic review by Manzia et al., nor in
our analysis due to the lack of significant data.
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In our study, we determined a small number (0.6%)
of patients transplanted due to NRH-syndrome, which
is lower than reported in several other studies, espe-
cially in thiopurine users.10,11,35 Many of these studies
reported the incidence rate of histological NRH, which
was not associated with a clinically signiﬁcant liver dis-
ease.4,40 However, our study is not comparable to these
studies since we only assessed patients with a clinically
signiﬁcant liver disease needing OLT. Nevertheless,
some patients with NRH-syndrome are appropriate
candidates for liver transplantation, but may have
absolute or relative contraindications for OLT. These
individuals were not included in our study, probably
leading to selection bias and an underestimation of
the incidence of disease.
Conclusion
In conclusion, a small number of patients, predomin-
antly young males, were transplanted due to severe
NRH-syndrome, concluding that this is a rare treat-
ment indication for liver transplantation. The clinical
manifestation of progressive NRH-syndrome is mainly
revealed by severe complications of portal hyperten-
sion. Furthermore, non-speciﬁc abnormalities in
laboratory parameters and imaging studies could
reveal the presence of NRH. Whilst it is known that
NRH is associated with several diseases and drugs, the
diagnosis should also be considered in patients without
a related medical history. Liver transplantation may
have an important role in NRH-syndrome but vigilance
is required, especially in patients suﬀering from HPS
and other severe portal hypertension complications.
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